Abstract 5635
Background
A cancer diagnosis often causes an emotional impact with signs of anxiety, uncertainty and subjective discomfort. It´s necessary to identify and assess emotional discomfort to offer quality treatment articulated around the patient and his / her demand. The design of a questionnaire that is easy to use and understand, allows the detection of patients susceptible to referral to the Psycho-oncology Unit (POU).
Methods
- Prepare a PAQ that includes: Evaluation of emotional distress assisted by visual analogue scales (VAS); Modified Gijón scale (sociofamilar assessment scale); previous use of psychoactive drugs - Include PAQ in the first nursing visit - Quick referral to POU - Interview with psycho-oncology nurse - Valuation, diagnosis and treatment planning by POU - Data recording - Data analysis.
Results
Patients with a positive PAQ are referred to the POU where the liaison nurse performs an interview with the patient and / or family. The nurse collects data on psychobiography, oncological disease, psychic sphere, frequent affections, previous contacts with psychologists / psychiatrists and treatments with psychoactive drugs. The POU will offer the patient the most appropriate resource for their needs (Psychotherapy, Psychopharmaceuticals, and Social Work Service).
Conclusions
The inclusion of the PAQ in the first visit of nursing allows the detection and early treatment of disorders in the psychosocial area. We achieve an optimal use of resources, a greater adherence to the proposed oncological treatment, alleviate problems that are found throughout the oncological treatment and improve the quality of life of our patients by reducing emotional discomfort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract
4634 - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas.
Presenter: Mohamed Salem
Session: Poster Display session 3
Resources:
Abstract